Predictors of Maintaining Inactive Disease After Etanercept Withdrawal, and Regaining Inactive Disease Status After Flare and Retreatment, in Adults with Non-radiographic Axial Spondyloarthritis: Results from RE-EMBARK Filip Van den Bosch, MD, PhD – Dept. of Rheumatology - Ghent University Hospital
4:10 PM – 4:20 PM ET
Therapeutic Drug Monitoring Compared to Standard Treatment of Patients Starting Infliximab: Results from a Multicenter Randomized Controlled Trial of 400 Patients Silje Watterdal W. Syversen, MD, PhD – Diakonhjemmet Hospital
4:20 PM – 4:30 PM ET
Treatment with Selective Cyclooxygenase-2 Inhibitors Is Associated with Inhibition of Radiographic Spinal Progression in Patients with Axial Spondyloarthritis: Long-term Results from the German Spondyloarthritis Inception Cohort Denis Poddubnyy, MD, MSc – Charité - Universitätsmedizin Berlin
4:30 PM – 4:40 PM ET
Which Disease Activity Outcome Measure Discriminates Best in Axial Spondyloarthritis? A Systematic Literature Review and Meta-analysis Augusta Ortolan, MD – University of Padova/Leiden University Medical Center
4:40 PM – 4:50 PM ET
Treatment Response to Biological Disease-modifying Anti-rheumatic Drugs Is Associated with Favorable Changes of the Body Composition in Patients with Ankylosing Spondylitis Valeria Rios Rodriguez, MD – Charité Universitätsmedizin Berlin
.png "Walter Maksymowych, MD, FRCPC photo")
